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Patients with advanced colorectal carcinoma have a poor prog-
nosis. Although approximately 70% of the patients with primary
disease may undergo an apparently curative resection, 40% will
develop recurrent disease within 5 years (McArdle et al, 1990).
Liver metastases are the major determinant of reduced survival
(Finley and McArdle, 1983) but it is still difficult to predict
patients at risk. Follow-up regimens after resection for primary
colorectal cancer in general consist of periodic interval history,
physical examinations and endoscopic surveillance. The useful-
ness of analysing consecutive serum carcinoembryonic antigen
(CEA) levels has been questioned (Kievit and Van der Velde,
1990; Virgo et al, 1995) but CEA is still used as an eventual
predictor of residual disease or metastases (Lucha et al, 1997).
YKL-40* is a mammalian member of the chitinase protein
family which has no chitinase activity (Nyirkos et al, 1990; Hakala
et al, 1993; Johansen et al, 1993; Shackelton et al, 1995; Hu et al,
1996; Kirkpatrick et al, 1997; Rehli et al, 1997; Renkema et al,
1998) but does bind chitin (Renkema et al, 1998). Although the
physiological function of YKL-40 is unknown, the pattern of its
expression in normal and disease state suggests a function in
remodelling or degradation of extracellular matrix. YKL-40 is
secreted in large amounts in vitro by the MG63 human osteo-
sarcoma cell line (Johansen et al, 1992) and is expressed selectively
by murine mammary tumours initiated by neu/ras oncogenes but
not by c-myc or int-2 oncogenes (Morrison and Leder, 1994).
Furthermore, YKL-40 is synthesized by activated macrophages
(Krause et al, 1996; Kirkpatrick et al, 1997; Renkema et al, 1998)
and the protein is present in the specific granules of neutrophils and
is exocytosed by activation (Volck et al, 1998).
The protein can be determined in serum by radioimmunoassay
(RIA) (Johansen et al, 1993). Recently, we demonstrated that
serum YKL-40 levels are elevated in patients with recurrent breast
cancer and metastases to bone or viscera and may be used as a
prognostic biochemical marker of survival (Johansen et al, 1995).
We have therefore studied whether YKL-40 is elevated in patients
with primary colorectal cancer and whether YKL-40 can be used
as a prognostic marker of survival.
MATERIALS AND METHODS
Patients
The study included 603 patients, 355 males and 248 females, with
a median age of 69 years (range 33–91 years), who underwent
primary elective large bowel resection for colorectal cancer. Three
hundred and fifty-five patients had cancer of the colon and 250
patients had rectal cancer. The patients, described in details else-
where (Nielsen et al, 1998), participated in a national multicentre
study, comprising 20 Danish hospital centres, performed between
1990 and 1997. Patients estimated as having a shorter survival
than 3 months were not included. Dukes’ stage and survival after
the operation were registered. None of the patients had an infec-
tion or was treated with steroids at time of operation. None of the
patients received postoperative adjuvant chemotherapy. Median
follow-up time was 61 months (range 45–75 months). The patients
were followed for death/survival by using their health security
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number (CPR) in the central national registry. No patients were
lost at follow-up. The endpoint was death of all causes and 340
patients died. Twenty patients who died within 1 month from
surgery of causes other than cancer were censored. The study was
performed in agreement with the Helsinki II declaration. The
research protocol was approved by the local ethical committee.
The patients were informed about the study verbally and in
writing. All gave their written consent. The patients were informed
about the possibility of withdrawing from the study at any time.
Controls
The controls comprised 260 persons, 116 males and 144 females,
with a median age of 48 years (range 18–79 years) (Johansen et al,
1996). The controls were blood donors who attended the Regional
Blood Transfusion Services at Hvidovre Hospital, people working
at different museums in Copenhagen and people living in a shared
house for elderly. All were healthy, were not taking any medicine,
and had no signs or clinical symptoms of cancer, joint, liver,
metabolic or hormonal disease. The median serum YKL-40 level
was 102 mg l–1 (range 38–514 mg l–1, upper 95th percentile =
247 mg l–1), with a weak correlation to age (Spearman = 0.30).
There was no difference between gender (P = 0.65, Wilcoxon 2-
sample test). A normal reference region was calculated on the log
transformed YKL-40 values as described by Royston (1991)
adjusting for age, the upper 95th per cent confidence limit was
chosen for the limit.
Biochemical analysis
Blood samples were taken in the morning before surgery and serum
was separated from cellular elements by centrifugation within 1 h of
sampling. All serum samples were stored at – 80°C until analysis.
Serum YKL-40 was determined by RIA (Johansen et al, 1993) using
rabbit antibody raised against human YKL-40. Purified human
YKL-40 was used for standard and tracer. The intra-assay and inter-
assay variations were < 6.5% and < 12% respectively, and the sensi-
tivity was 20 mg l–1. CEA was measured in serum using the Immulite
CEA assay (Euro/DPC Ltd, Llanberis, Gwynedd, UK).
Statistical analysis
The statistical analysis was done with SASR (SAS Institute, Cary,
NC, USA). Tests for homogeneity between covariates were done
using the chi-square. Survival curves were estimated by the
Kaplan–Meier method. The log-rank test was used for test of
homogeneity between strata. Multivariate survival analyses were
performed with the Cox proportional hazards model. The assump-
tion of proportional hazards was verified graphically. The endpoint
was death of all causes (overall survival). The serum YKL-40
covariate was dichotomized by the normal reference region as
described above. The other covariates included in the multivariate
analysis of Cox were serum CEA [dichotomized by its median
level (3.8 mg l–1)], Dukes’ stage (entered as indicator variable),
gender and age.
RESULTS
The distribution by Dukes’ staging was 58 in A, 223 in B, 175 in C
and 147 in D. Median follow-up time was 61 months (range 45–75
months) and in this period 340 patients died. The median preoper-
ative serum YKL-40 concentration in all patients was 180 mg l–1
(range 56–2709 mg l–1). The number of patients with YKL-40
levels above the age-corrected 95th percentile of normal controls
was 159. There was no significant difference between high serum
YKL-40 and gender (P = 0.07, Wilcoxon rank sum test) but there
was a relatively weak correlation to age (Spearman = 0.30, P <
0.0001). Sixteen per cent of the patients with Dukes’ A, 26% with
Dukes’ B, 19% with Dukes’ C, and 39% with Dukes’ D had
increased levels of serum YKL-40, i.e. a serum YKL-40 level
above the age-corrected 95th percentile of normal controls. Figure
1 shows the individual serum YKL-40 values according to Dukes
stage. The chi-square showed a significant association between
serum YKL-40 and Dukes’ stage (P = 0.001).
Analysis of the serum YKL-40 value as a continuous variable
showed a highly significant association between increased serum
YKL-40 and short survival (P < 0.0001). Figure 2 illustrates the
survival plot when the patients were grouped by quartiles according
to their preoperative serum YKL-40 level: Group 1, patients with a
serum YKL-40 ≤ 120 mg l–1 (n = 161); Group 2, patients with a
serum YKL-40 > 120 and ≤ 180 mg l–1 (n = 141); Group 3, patients
with a serum YKL-40 > 180 and ≤ 304 mg l–1 (n = 152) and Group 4,
patients with a serum YKL-40 > 304 mg l–1 (n = 149).
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Figure 1 The figure shows the YKL-40 values in each Dukes stage. The
solid and dotted lines indicate the mean and upper 95% limit values for
YKL-40 predicted for normal 70-year-old subjects (the median age for colon
cancer subjects in the present study is 69 years)1496 C Cintin et al
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When all the patients were grouped by a high (versus normal,
age-corrected) preoperative serum YKL-40 concentration, the
group with high YKL-40 had significantly shorter survival than
patients with a normal preoperative serum YKL-40 [Hazard ratio
(HR) of 1.7; 95% confidence interval (CI): 1.3–2.1, P < 0.0001].
The Kaplan–Meier plot for all patients is shown in Figure 3A,
Dukes’ B patients in Figure 3B, Dukes’ C patients in Figure 3C
and Dukes’ D patients in Figure 3D. The Kaplan–Meier plot was
not evaluated for patients with Dukes’ A due to the low number of
patients and events.
Univariate survival analysis of the other included covariates
showed that Dukes’ stage was highly significant (P < 0.0001), as
well as age (in years, P = 0.002) and CEA (P < 0.0001, HR = 1.9,
95% CI: 1.5–2.3), whereas gender was not (P = 0.17).
A multivariate Cox analysis including serum YKL-40, serum
CEA, Dukes’ stages, age and gender showed that a high YKL-40
was an independent prognostic parameter for short survival, with a
HR of 1.4 (95% CI: 1.1–1.8, P = 0.007) (Table 1). Dukes’ staging
was the strongest independent prognostic variable and age was
also a significant independent prognostic parameter of survival.
Serum CEA and gender were not significant prognostic parameters
of survival.
A multivariate Cox analysis including only serum YKL-40 and
serum CEA (n = 598) showed that both parameters were indepen-
dent prognostic parameters of survival (P < 0.0001) with a HR of
1.6 (95% CI: 1.3–2.0) for serum YKL-40 and 1.9 (95% CI:
1.5–2.3) for serum CEA. There was no significant difference
between high YKL-40 plus low CEA compared to low YKL-40
plus high CEA (P = 0.15). When YKL-40 and CEA were
combined, a highly significant separation (P < 0.0001) was
obtained between patients with both high serum YKL-40 and high
serum CEA (n = 84) and patients with normal levels of both para-
meters (n = 231) with a HR of 3.3 (95% CI: 2.4–4.4) (Figure 4).
DISCUSSION
Dukes’ staging is a well-established strong prognostic indicator of
survival in patients suffering from colorectal cancer (Dukes and
Bussey, 1958; Wiggers et al, 1988; Ståhle et al, 1989). However, a
considerable variation in prognosis has been demonstrated within
each stage (Jass et al, 1987; Newland et al, 1987) and some
patients with Dukes’ stage B have a poorer prognosis than patients
in Dukes’ C. Several studies have been performed to find new
biochemical markers in order to identify patients at high risk for
recurrence, who might be candidates for additional therapy after
surgery. There are numerous reports on CEA in screening and
follow-up of patients with colorectal cancer, but this marker seems
to be of limited clinical use (Kievit and Van der Velde, 1990; Virgo
et al, 1995; Lucha et al, 1997). Nevertheless, the most frequently
used marker is still CEA.
We recently examined serum YKL-40 in patients with cancer
mamma and found that high levels of YKL-40 are a prognostic
indicator of a significantly shorter survival (Johansen et al, 1995).
In the present study we evaluated the possible relationship
between the preoperative level of YKL-40 in serum and the
survival of the patients after surgery for colorectal cancer. A strong
association was found between short survival and high preopera-
tive YKL-40 levels. A significant relation was also found between
serum YKL-40 and Dukes’ stage, but multivariate Cox analysis
showed that serum YKL-40 was a prognostic variable of survival,
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Figure 2 The impact of serum YKL-40 level on overall survival of colorectal
cancer patients. Patients were divided into four groups according to the
serum level of YKL-40 obtained preoperatively: Group 1 (— —), patients with
serum YKL-40 ≤ 120 mg l–1 (n = 161); Group 2 (- -), patients with a serum
YKL-40 > 120 and ≤ 180 mg l–1 (n = 141); Group 3 (–), patients with a serum
YKL-40 > 180 and ³ 304 mg l–1 (n = 152); and Group 4 (– -), patients with a
serum YKL-40 > 304 mg l–1 (n = 149). The number of events are shown for
each group at the left, and the number of patients at risk are shown for 0, 12,
24, 36 and 48 months
Table 1 Independent prognostic variables from the Cox multivariate
analysis
Covariate P-value HR 95% CI
YKL-40 0.007 1.4 1.1–1.8
(high vs normal)
CEA 0.10
(high vs. low)
Age (years) 0.0002 1.4a 1.3–1.5
Dukes’ B 0.003 3.2 1.5–6.9
(vs Dukes A)
Dukes’ C 0.0001 7.0 3.3–15.1
(vs Dukes A)
Dukes’ D 0.0001 27.2 12.6–58.4
(vs Dukes A)
Gender 0.1
(male/female)
HR, relative hazard ratio; CI, confidence interval. aHR for two patients
differing in age by 15 years.Serum YKL-40 and colorectal cancer 1497
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independent of Dukes’ stage. If preoperative high levels of YKL-
40 do prove to identify patients in Dukes’ B and C with a high risk
of recurrence, more intensive follow-up and treatment could be
given to these patients, such as adjuvant therapy or reoperation.
The precise sources of YKL-40 which lead to elevated serum
levels of the protein in some colorectal cancer patients are not yet
known. Serum YKL-40 could in principle arise from secretion by
the tumour cells themselves, from secretion by inflammatory cells,
and from secretion by normal cells in areas of the colon adjacent to
the tumour. We are currently investigating the expression of YKL-
40 in colon cancer biopsies using immunohistochemical methods.
Preliminary data show that some colon cancers stain intensely for
YKL-40 while other colon cancers are completely negative.
Normal intestinal epithelium distant from the areas of neoplasia
are negative. Although some YKL-40 staining can be seen in
mononuclear cells located in the connective tissue, there is no
difference in mononuclear staining between connective tissue
areas adjacent to the tumour and areas distant from the tumour
(personal observation). Some support for the hypothesis that
YKL-40 may be secreted by a subset of colorectal tumours is
provided by the observation that the protein is strongly expressed
by murine mammary tumours initiated by neu/ras oncogenes but
is not expressed by mammary tumours initiated by c-myc or by
int-2 (Morrison and Leder, 1994). It is of interest to note that the
investigators who made these observations on mammary tumours
independently concluded that YKL-40 could be a marker for a
subset of human breast cancers, without knowledge of our contem-
poraneous study that showed that serum YKL-40 is, in fact, a
prognostic indicator of survival in patients with recurrent breast
cancer (Johansen et al, 1995).
If elevated levels of serum YKL-40 do primarily reflect secre-
tion from a subset of colorectal tumours, then the poor prognosis
of patients with elevated serum YKL-40 suggests that YKL-40
expression may be associated with the ability of a tumour cell to
invade normal tissues and to metastasize to distant sites. It is also
possible that the as yet unknown function of YKL-40 itself may be
important to an aspect of tumour invasiveness.
Recent studies have shown that YKL-40 is a chitin-binding
lectin (Renkema et al, 1998). Chitin is a homopolymer of N-
acetyl-D-glucosamine in b 1–4 linkage, which is found in the cell
wall of fungi and in the exoskeleton of insects, crustaceans and
arthropods, but not in any mammalian tissue (Skjak-Braek et al,
1989). The functional ligand for the chitin binding site in YKL-40
is not presently known. Other lectins have been found at elevated
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Figure 3 The impact of serum YKL-40 level on overall survival of colorectal cancer patients. Patients were grouped by a high (vs normal) preoperative serum
YKL-40 concentration adjusted for age. The cut-off limit used was 95th confidence limit of healthy age-matched subjects: patients with normal serum YKL-40
(N —) and patients with elevated serum YKL-40 levels (H- - -). A illustrates the results of all patients (HR = 1.7, 95%CI: 1.3–2.1, P = 0.0001). B illustrates the
results in patients with Dukes’ B (HR = 1.6, 95% CI: 1.0–2.5 P = 0.07), C, the patients with Dukes’ C (HR = 1.4, 95% CI: 0.8–2.2, P = 0.21) and D the results in
patients with Dukes’ D (HR = 1.3, 95% CI: 0.9–1.8, P = 0.15). The number of events are shown for each group at the left, and the number of patients at risk are
shown for 0, 12, 24, 36 and 48 months
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levels in a variety of neoplastic cells, and studies suggest that some
of these lectins are involved as adhesion molecules for tumour
metastasis in vivo (Raz et al, 1990; Schoeppner et al, 1995;
Bressalier et al, 1996). In colon cancer lectin binding has been
linked to tumour progression and K-ras activation (Wojciechowicz
et al, 1995).
As part of this multicentre colorectal cancer study, each primary
tumour has been fixed for possible histological analyses and serum
samples have been obtained periodically following surgery for
removal of the primary tumour. In future studies we intend to use
immunohistochemistry to establish the pattern of YKL-40 expres-
sion in colorectal tumours obtained from patients with elevated as
well as normal serum YKL-40 levels, and we will examine the
longitudinal relationship between serum YKL-40 levels and
survival.
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APPENDIX
The following investigators participated in The RANX05
Colorectal Cancer Study Group.
Bispebjerg Hospital: S Schulze, MD, DMSc
J Thorup, MD
P Wille-Jørgensen, MD, DMSc
Bornholm Hospital: E Bentzen, MD
Frederiksberg Hospital: I Christoffersen, MD
P Møller, MD
Frederikssund Hospital: L Banke, MD, DMSc
D Froberg, MD
Gentofte Hospital: FW Henriksen, MD, DMSc
P Crone, MD
Glostrup Hospital: P Hesselfeldt, MD
B Hempel Sparsø, MD
K Lindorff Larsen, MD
Helsingør Hospital: T Asmussen, MD
J Heiner, MD
Hillerød Hospital: O Hart Hansen, MD, DMSc
H Flyger, MD, PhD
P Jess, MD, DMSc
Holbæk Hospital: J Iversen, MD
J La Cour-Andersen, MD, DMSc
B Vennits, MD
Hvidovre Hospital: F Moesgaard, MD, DMSc
J Hammer, MD
Hørsholm Hospital: A Fischer, MD, DMSc
H Galatius, MD
Kalundborg Hospital: L Naver, MD
Køge Hospital: D Teilum, MD
Nykøbing Falster Hospital: L Holbraad, MD
Næstved Hospital: O Iversen, MD, DMSc
J Nymark, MD
O Roikjær, MD
Rigshospitalet: LB Svendsen, MD, DMSc
L Vedel, MD
Roskilde Hospital: L Palm, MD, DMSC
KC Rasmussen, MD
Slagelse Hospital: J Friis, MD
C Lanng, MD
K Wiboltt, MD
Stege Hospital: NC Jensen, MD
N Hoffman, MD
Sundby Hospital: T Larsen, MD
J Packler, MD